24Nov 2023
Efficacy and safety of first-line combination therapy versus monotherapy for vitreoretinal lymphoma

Efficacy and safety of first-line combination therapy versus monotherapy for vitreoretinal lymphoma

This systematic review compared the efficacy and safety of combination therapy and monotherapy in 517 vitreoretinal lymphoma (VRL) patients. The combined therapy group, using various combinations of intraocular methotrexate, chemotherapy, radiotherapy, and lenalidomide/bruton’s tyrosine kinase inhibitors (BTKi), exhibited higher overall and complete response rates compared to the monotherapy group mainly treated with oral BTKi. Despite improved progression-free survival with combination therapy, it also presented higher grade 3/4 toxicity. The study suggests that while combination therapy is more effective, the long-term benefits and tolerability of BTK inhibitors need further investigation.

  • #ophthalmology

Like

Save

Share